Atypical haemolytic uraemic syndrome (aHUS)

A case of satisfactory management with eculizumab

Abstract

Atypical haemolytic uraemic syndrome (aHUS) constitutes a diagnosis of exclusion that should be considered in the presence of microangiopathic hemolytic anemia, thrombocytopenia and acute renal injury. It is associated with mutations that cause a dysregulation of the complement system and implies an adverse prognosis and high risk of progression to chronic kidney disease. Next, we present the case of a patient with aHUS, highlighting the effect and importance of biological therapy with the monoclonal antibody eculizumab